AVAC

Drug Profile

AVAC

Alternative Names: AVAC

Latest Information Update: 16 May 2007

Price : $50

At a glance

  • Originator Genesis Research and Development
  • Developer SR Pharma
  • Class Antiasthmatics; Skin disorder therapies; Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma; Atopic dermatitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Dec 2004 Discontinued - Phase-II for Atopic dermatitis in New Zealand (Intradermal)
  • 04 Jun 2004 AVAC or SRP 299 will be available for licensing on completion of current phase II trials (http://www.genesis.co.nz)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top